Understanding response and resistance to oestrogen deprivation in ER-positive breast cancer

Molecular and Cellular Endocrinology

Volumn 382, Issue 1, 2014, Pages 683-694

  Patani, N ^a,b   Martin, L A ^b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Aromatase inhibitor; Breast cancer; Oestrogen deprivation; Oestrogen receptor; Resistance; Sensitivity

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; ANDROGEN; ANTINEOPLASTIC AGENT; AROMATASE; AROMATASE INHIBITOR; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYTOCHROME P450; DASATINIB; ENTINOSTAT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN; ESTROGEN RECEPTOR ALPHA; EVEROLIMUS; EXEMESTANE; FADROZOLE; FORMESTANE; FULVESTRANT; LETROZOLE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PALBOCICLIB; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PLACEBO; PROGESTERONE; PROTEIN KINASE B INHIBITOR; PYRIDOGLUTETHIMIDE; TAMOXIFEN; UNINDEXED DRUG; VOROZOLE;

ADJUVANT THERAPY; BREAST CANCER; CANCER HORMONE THERAPY; CANCER RECURRENCE; DISEASE COURSE; DISEASE MARKER; DRUG DESIGN; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; DRUG RESISTANCE; DRUG RESPONSE; DRUG SPECIFICITY; DRUG TOLERABILITY; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; ESTROGEN SYNTHESIS; HUMAN; IN VITRO STUDY; METASTASIS; PATIENT SELECTION; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; STEROIDOGENESIS; STOMATITIS;

AROMATASE INHIBITOR; BREAST CANCER; OESTROGEN DEPRIVATION; OESTROGEN RECEPTOR; RESISTANCE; SENSITIVITY;

AROMATASE INHIBITORS; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; ESTROGENS; FEMALE; HUMANS; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION;

EID: 84888311174     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2013.09.038     Document Type: Review

References (161)

1. Ali S., Coombes R.C. Endocrine-responsive breast cancer and strategies for combating resistance. Nature Reviews Cancer 2002, 2(2):101-112.
2. Ali S., Metzger D., Bornert J.M., Chambon P. Modulation of transcriptional activation by ligand-dependent phosphorylation of the human oestrogen receptor A/B region. The EMBO Journal 1993, 12(3):1153-1160.
3. Anderson W.F., Chatterjee N., Ershler W.B., Brawley O.W. Estrogen receptor breast cancer phenotypes in the surveillance, epidemiology, and end results database. Breast Cancer Research and Treatment 2002, 76(1):27-36.
4. Arnedos M., Drury S., Afentakis M., Hills M., Salter J., Smith I., Dowsett M. Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in ER-positive breast cancer. Journal of Clinical Oncology 2010, 28(15):1034.
5. Arnold S.F., Obourn J.D., Jaffe H., Notides A.C. Serine 167 is the major estradiol-induced phosphorylation site on the human estrogen receptor. Molecular Endocrinology 1994, 8(9):1208-1214.
6. Bachelot T., Bourgier C., Cropet C., Ray-Coquard I., Ferrero J.M., Freyer G., Abadie-Lacourtoisie S., Eymard J.C., Debled M., Spaeth D., et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2012, 30(22):2718-2724.
7. Barton M. Cholesterol and atherosclerosis: modulation by oestrogen. Current Opinion in Lipidology 2013, 24(3):214-220.
8. Baselga J., Campone M., Piccart M., Burris H.A., Rugo H.S., Sahmoud T., Noguchi S., Gnant M., Pritchard K.I., Lebrun F., et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. The New England Journal of Medicine 2012, 366(6):520-529.
9. Baum M., Buzdar A., Cuzick J., Forbes J., Houghton J., Howell A., Sahmoud T. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003, 98(9):1802-1810.
10. Bautista S., Valles H., Walker R.L., Anzick S., Zeillinger R., Meltzer P., Theillet C. In breast cancer, amplification of the steroid receptor coactivator gene AIB1 is correlated with estrogen and progesterone receptor positivity. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 1998, 4(12):2925-2929.
11. Beatson G.T. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Lancet 1896, 2:104-107.
12. Benecke A., Chambon P., Gronemeyer H. Synergy between estrogen receptor alpha activation functions AF1 and AF2 mediated by transcription intermediary factor TIF2. EMBO Reports 2000, 1(2):151-157.
13. Bergh J., Jonsson P.E., Lidbrink E.K., Trudeau M., Eiermann W., Brattstrom D., Lindemann J.P., Wiklund F., Henriksson R. FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2012, 30(16):1919-1925.
14. Bhatnagar A.S., Hausler A., Schieweck K., Lang M., Bowman R. Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new non-steroidal aromatase inhibitor. The Journal of Steroid Biochemistry and Molecular Biology 1990, 37(6):1021-1027.
15. Bhat-Nakshatri P., Wang G., Appaiah H., Luktuke N., Carroll J.S., Geistlinger T.R., Brown M., Badve S., Liu Y., Nakshatri H. AKT alters genome-wide estrogen receptor alpha binding and impacts estrogen signaling in breast cancer. Molecular and Cellular Biology 2008, 28(24):7487-7503.
16. Biddie S.C., John S., Hager G.L. Genome-wide mechanisms of nuclear receptor action. Trends in Endocrinology and Metabolism: TEM 2010, 21(1):3-9.
17. Bisagni G., Cocconi G., Scaglione F., Fraschini F., Pfister C., Trunet P.F. Letrozole, a new oral non-steroidal aromastase inhibitor in treating postmenopausal patients with advanced breast cancer. A pilot study. Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO 1996, 7(1):99-102.
18. Bonneterre J., Thurlimann B., Robertson J.F., Krzakowski M., Mauriac L., Koralewski P., Vergote I., Webster A., Steinberg M., von Euler M. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2000, 18(22):3748-3757.
19. Brodie A., Jelovac D., Long B.J. Predictions from a preclinical model: studies of aromatase inhibitors and antiestrogens. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2003, 9(1 Pt 2):455S-459S.
20. Brzozowski A.M., Pike A.C., Dauter Z., Hubbard R.E., Bonn T., Engstrom O., Ohman L., Greene G.L., Gustafsson J.A., Carlquist M. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 1997, 389(6652):753-758.
21. Burstein H.J., Prestrud A.A., Seidenfeld J., Anderson H., Buchholz T.A., Davidson N.E., Gelmon K.E., Giordano S.H., Hudis C.A., Malin J., et al. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2010, 28(23):3784-3796.
22. Buzdar A., Jonat W., Howell A., Jones S.E., Blomqvist C., Vogel C.L., Eiermann W., Wolter J.M., Azab M., Webster A., et al. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 1996, 14(7):2000-2011.
23. Buzdar A., Douma J., Davidson N., Elledge R., Morgan M., Smith R., Porter L., Nabholtz J., Xiang X., Brady C. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2001, 19(14):3357-3366.
24. Byar D.P., Sears M.E., McGuire W.L. Relationship between estrogen receptor values and clinical data in predicting the response to endocrine therapy for patients with advanced breast cancer. European Journal of Cancer 1979, 15(3):299-310.
25. Campbell R.A., Bhat-Nakshatri P., Patel N.M., Constantinidou D., Ali S., Nakshatri H. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. The Journal of Biological Chemistry 2001, 276(13):9817-9824.
26. Celik L., Lund J.D., Schiott B. Conformational dynamics of the estrogen receptor alpha: molecular dynamics simulations of the influence of binding site structure on protein dynamics. Biochemistry 2007, 46(7):1743-1758.
27. Chan C.M., Martin L.A., Johnston S.R., Ali S., Dowsett M. Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation. The Journal of Steroid Biochemistry and Molecular Biology 2002, 81(4-5):333-341.
28. Chen D., Washbrook E., Sarwar N., Bates G.J., Pace P.E., Thirunuvakkarasu V., Taylor J., Epstein R.J., Fuller-Pace F.V., Egly J.M., et al. Phosphorylation of human estrogen receptor alpha at serine 118 by two distinct signal transduction pathways revealed by phosphorylation-specific antisera. Oncogene 2002, 21(32):4921-4931.
29. Chia S., Gradishar W., Mauriac L., Bines J., Amant F., Federico M., Fein L., Romieu G., Buzdar A., Robertson J.F., et al. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2008, 26(10):1664-1670.
30. Cummings S.R., Black D.M., Thompson D.E., Applegate W.B., Barrett-Connor E., Musliner T.A., Palermo L., Prineas R., Rubin S.M., Scott J.C., et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA, The Journal of the American Medical Association 1998, 280(24):2077-2082.
31. Cuzick J., Powles T., Veronesi U., Forbes J., Edwards R., Ashley S., Boyle P. Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003, 361(9354):296-300.
32. Dauvois S., Danielian P.S., White R., Parker M.G. Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. Proceedings of the National Academy of Sciences of the United States of America 1992, 89(9):4037-4041.
33. Dauvois S., White R., Parker M.G. The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. Journal of Cell Science 1993, 106(Pt 4):1377-1388.
34. Davies C., Godwin J., Gray R., Clarke M., Cutter D., Darby S., McGale P., Pan H.C., Taylor C., Wang Y.C., et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011, 378(9793):771-784.
35. Deyarmin B., Kane J.L., Valente A.L., van Laar R., Gallagher C., Shriver C.D., Ellsworth R.E. Effect of ASCO/CAP guidelines for determining ER status on molecular subtype. Annals of Surgical Oncology 2013, 20(1):87-93.
36. Dodwell D., Coombes G., Bliss J.M., Kilburn L.S., Johnston S. Combining fulvestrant (Faslodex) with continued oestrogen suppression in endocrine-sensitive advanced breast cancer: the SoFEA trial. Clinical Oncology (Royal College of Radiologists) 2008, 20(5):321-324.
37. Dombernowsky P., Smith I., Falkson G., Leonard R., Panasci L., Bellmunt J., Bezwoda W., Gardin G., Gudgeon A., Morgan M., et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 1998, 16(2):453-461.
38. Dong L., Wang W., Wang F., Stoner M., Reed J.C., Harigai M., Samudio I., Kladde M.P., Vyhlidal C., Safe S. Mechanisms of transcriptional activation of bcl-2 gene expression by 17beta-estradiol in breast cancer cells. The Journal of Biological Chemistry 1999, 274(45):32099-32107.
39. Dowsett M., Stein R.C., Mehta A., Coombes R.C. Potency and selectivity of the non-steroidal aromatase inhibitor CGS 16949A in postmenopausal breast cancer patients. Clinical Endocrinology 1990, 32(5):623-634.
40. Dowsett M., Stein R.C., Coombes R.C. Aromatization inhibition alone or in combination with GnRH agonists for the treatment of premenopausal breast cancer patients. The Journal of Steroid Biochemistry and Molecular Biology 1992, 43(1-3):155-159.
41. Dowsett M., Harper-Wynne C., Boeddinghaus I., Salter J., Hills M., Dixon M., Ebbs S., Gui G., Sacks N., Smith I. HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer. Cancer Research 2001, 61(23):8452-8458.
42. Dowsett M., Allred C., Knox J., Quinn E., Salter J., Wale C., Cuzick J., Houghton J., Williams N., Mallon E., et al. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2008, 26(7):1059-1065.
43. Early Breast Cancer Trialists' Collaborative Group Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998, 351(9114):1451-1467.
44. Early Breast Cancer Trialists' Collaborative Group Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365(9472):1687-1717.
45. Eiermann W., Paepke S., Appfelstaedt J., Llombart-Cussac A., Eremin J., Vinholes J., Mauriac L., Ellis M., Lassus M., Chaudri-Ross H.A., et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO 2001, 12(11):1527-1532.
46. Ellis M.J., Coop A., Singh B., Mauriac L., Llombert-Cussac A., Janicke F., Miller W.R., Evans D.B., Dugan M., Brady C., et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2001, 19(18):3808-3816.
47. Ellis M.J., Coop A., Singh B., Tao Y., Llombart-Cussac A., Janicke F., Mauriac L., Quebe-Fehling E., Chaudri-Ross H.A., Evans D.B., et al. Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. Cancer Research 2003, 63(19):6523-6531.
48. Evans C.T., Ledesma D.B., Schulz T.Z., Simpson E.R., Mendelson C.R. Isolation and characterization of a complementary DNA specific for human aromatase-system cytochrome P-450 mRNA. Proceedings of the National Academy of Sciences of the United States of America 1986, 83(17):6387-6391.
49. Evinger A.J., Levin E.R. Requirements for estrogen receptor alpha membrane localization and function. Steroids 2005, 70(5-7):361-363.
50. Fawell S.E., White R., Hoare S., Sydenham M., Page M., Parker M.G. Inhibition of estrogen receptor-DNA binding by the "pure" antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization. Proceedings of the National Academy of Sciences of the United States of America 1990, 87(17):6883-6887.
51. Finn R.S. Results of a randomized phase 2 study of PD 0332991, a cyclindependent kinase (CDK) 4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER/HER2- advanced breast cancer (BC). Cancer Research 2012, 72(Suppl.):24.
52. Finn R.S., Dering J., Conklin D., Kalous O., Cohen D.J., Desai A.J., Ginther C., Atefi M., Chen I., Fowst C., et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Research: BCR 2009, 11(5):R77.
53. Fisher B., Costantino J.P., Wickerham D.L., Redmond C.K., Kavanah M., Cronin W.M., Vogel V., Robidoux A., Dimitrov N., Atkins J., et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. Journal of the National Cancer Institute 1998, 90(18):1371-1388.
54. Garcia-Bassets I., Kwon Y.S., Telese F., Prefontaine G.G., Hutt K.R., Cheng C.S., Ju B.G., Ohgi K.A., Wang J., Escoubet-Lozach L., et al. Histone methylation-dependent mechanisms impose ligand dependency for gene activation by nuclear receptors. Cell 2007, 128(3):505-518.
55. Gaub M.P., Bellard M., Scheuer I., Chambon P., Sassone-Corsi P. Activation of the ovalbumin gene by the estrogen receptor involves the fos-jun complex. Cell 1990, 63(6):1267-1276.
56. Geisler J., Haynes B., Anker G., Dowsett M., Lonning P.E. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2002, 20(3):751-757.
57. Gershanovich M., Chaudri H.A., Campos D., Lurie H., Bonaventura A., Jeffrey M., Buzzi F., Bodrogi I., Ludwig H., Reichardt P., et al. Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3). Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO 1998, 9(6):639-645.
58. Gibson M.K., Nemmers L.A., Beckman W.C., Davis V.L., Curtis S.W., Korach K.S. The mechanism of ICI 164,384 antiestrogenicity involves rapid loss of estrogen receptor in uterine tissue. Endocrinology 1991, 129(4):2000-2010.
59. Girault I., Lerebours F., Amarir S., Tozlu S., Tubiana-Hulin M., Lidereau R., Bieche I. Expression analysis of estrogen receptor alpha coregulators in breast carcinoma: evidence that NCOR1 expression is predictive of the response to tamoxifen. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2003, 9(4):1259-1266.
60. Goldhirsch A., Ingle J.N., Gelber R.D., Coates A.S., Thurlimann B., Senn H.J. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO 2009, 20(8):1319-1329.
61. Goss P.E., Strasser K. Tamoxifen resistant and refractory breast cancer: the value of aromatase inhibitors. Drugs 2002, 62(6):957-966.
62. Graves P.E., Salhanick H.A. Stereoselective inhibition of aromatase by enantiomers of aminoglutethimide. Endocrinology 1979, 105(1):52-57.
63. Harada N., Utsumi T., Takagi Y. Tissue-specific expression of the human aromatase cytochrome P-450 gene by alternative use of multiple exons 1 and promoters, and switching of tissue-specific exons 1 in carcinogenesis. Proceedings of the National Academy of Sciences of the United States of America 1993, 90(23):11312-11316.
64. Harper-Wynne C.L., Sacks N.P., Shenton K., MacNeill F.A., Sauven P., Laidlaw I.J., Rayter Z., Miall S., Howes A., Salter J., et al. Comparison of the systemic and intratumoral effects of tamoxifen and the aromatase inhibitor vorozole in postmenopausal patients with primary breast cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2002, 20(4):1026-1035.
65. Howell A., Robertson J.F., Quaresma Albano J., Aschermannova A., Mauriac L., Kleeberg U.R., Vergote I., Erikstein B., Webster A., Morris C. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2002, 20(16):3396-3403.
66. Huang H.J., Norris J.D., McDonnell D.P. Identification of a negative regulatory surface within estrogen receptor alpha provides evidence in support of a role for corepressors in regulating cellular responses to agonists and antagonists. Molecular Endocrinology 2002, 16(8):1778-1792.
67. Iwamoto T., Booser D., Valero V., Murray J.L., Koenig K., Esteva F.J., Ueno N.T., Zhang J., Shi W., Qi Y., et al. Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2012, 30(7):729-734.
68. Jeng M.H., Yue W., Eischeid A., Wang J.P., Santen R.J. Role of MAP kinase in the enhanced cell proliferation of long term estrogen deprived human breast cancer cells. Breast Cancer Research and Treatment 2000, 62(3):167-175.
69. Joel P.B., Smith J., Sturgill T.W., Fisher T.L., Blenis J., Lannigan D.A. Pp90rsk1 regulates estrogen receptor-mediated transcription through phosphorylation of Ser-167. Molecular and Cellular Biology 1998, 18(4):1978-1984.
70. Johnston S.R. BOLERO-2 - will this change practice in advanced breast cancer?. Breast Cancer Research: BCR 2012, 14(3):311.
71. Johnston S.R., Dowsett M. Aromatase inhibitors for breast cancer: lessons from the laboratory. Nature Reviews Cancer 2003, 3(11):821-831.
72. Johnston S.R., Schiavon G. Treatment algorithms for hormone receptor-positive advanced breast cancer. American Society of Clinical Oncology Educational Book/ASCO American Society of Clinical Oncology Meeting 2013, 2013:28-36.
73. Johnston S.R., Lu B., Dowsett M., Liang X., Kaufmann M., Scott G.K., Osborne C.K., Benz C.C. Comparison of estrogen receptor DNA binding in untreated and acquired antiestrogen-resistant human breast tumors. Cancer Research 1997, 57(17):3723-3727.
74. Johnston S., Pippen J., Pivot X., Lichinitser M., Sadeghi S., Dieras V., Gomez H.L., Romieu G., Manikhas A., Kennedy M.J., et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2009, 27(33):5538-5546.
75. Johnston, S., Kilburn, L.S., Ellis, P., Cameron, D., Dodwell, D., Howell, A., Im, Y.H., Coombes, G., Dowsett, M., Bliss, J.M., 2012. 2LBA fulvestrant alone or with concomitant anastrozole vs exemestane following progression on non-steroidal aromatase inhibitor - first results of the SoFEa trial (CRUKE/03/021 & CRUK/09/007) (ISRCTN44195747). European Journal of Cancer (Oxford, England: 1990), 48, S2.
76. Kao Y.C., Cam L.L., Laughton C.A., Zhou D., Chen S. Binding characteristics of seven inhibitors of human aromatase: a site-directed mutagenesis study. Cancer Research 1996, 56(15):3451-3460.
77. Kato S., Endoh H., Masuhiro Y., Kitamoto T., Uchiyama S., Sasaki H., Masushige S., Gotoh Y., Nishida E., Kawashima H., et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 1995, 270(5241):1491-1494.
78. Kaufmann M., Bajetta E., Dirix L.Y., Fein L.E., Jones S.E., Zilembo N., Dugardyn J.L., Nasurdi C., Mennel R.G., Cervek J., et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2000, 18(7):1399-1411.
79. Kelly M.J., Levin E.R. Rapid actions of plasma membrane estrogen receptors. Trends in Endocrinology and Metabolism: TEM 2001, 12(4):152-156.
80. Key T., Appleby P., Barnes I., Reeves G. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. Journal of the National Cancer Institute 2002, 94(8):606-616.
81. Kristensen V.N., Andersen T.I., Lindblom A., Erikstein B., Magnus P., Borresen-Dale A.L. A rare CYP19 (aromatase) variant may increase the risk of breast cancer. Pharmacogenetics 1998, 8(1):43-48.
82. Kumar V., Green S., Stack G., Berry M., Jin J.R., Chambon P. Functional domains of the human estrogen receptor. Cell 1987, 51(6):941-951.
83. Kurokawa H., Arteaga C.L. Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2001, 7(12 Suppl). 4436s-4442s; discussion 4411s-4412s.
84. Le Goff P., Montano M.M., Schodin D.J., Katzenellenbogen B.S. Phosphorylation of the human estrogen receptor. Identification of hormone-regulated sites and examination of their influence on transcriptional activity. The Journal of Biological Chemistry 1994, 269(6):4458-4466.
85. Levin E.R. Cellular functions of the plasma membrane estrogen receptor. Trends in Endocrinology and Metabolism: TEM 1999, 10(9):374-377.
86. Levin E.R. Minireview. Extranuclear steroid receptors: roles in modulation of cell functions. Molecular Endocrinology 2011, 25(3):377-384.
87. Levin E.R., Pietras R.J. Estrogen receptors outside the nucleus in breast cancer. Breast Cancer Research and Treatment 2008, 108(3):351-361.
88. Love R.R., Philips J. Oophorectomy for breast cancer: history revisited. Journal of the National Cancer Institute 2002, 94(19):1433-1434.
89. Love R.R., Mazess R.B., Barden H.S., Epstein S., Newcomb P.A., Jordan V.C., Carbone P.P., DeMets D.L. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. The New England Journal of Medicine 1992, 326(13):852-856.
90. Love R.R., Barden H.S., Mazess R.B., Epstein S., Chappell R.J. Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years. Archives of Internal Medicine 1994, 154(22):2585-2588.
91. Lupien M., Meyer C.A., Bailey S.T., Eeckhoute J., Cook J., Westerling T., Zhang X., Carroll J.S., Rhodes D.R., Liu X.S., et al. Growth factor stimulation induces a distinct ER(alpha) cistrome underlying breast cancer endocrine resistance. Genes & Development 2010, 24(19):2219-2227.
92. Mackay A., Urruticoechea A., Dixon J.M., Dexter T., Fenwick K., Ashworth A., Drury S., Larionov A., Young O., White S., et al. Molecular response to aromatase inhibitor treatment in primary breast cancer. Breast Cancer Research: BCR 2007, 9(3):R37.
93. MacNeill F.A., Jones A.L., Jacobs S., Lonning P.E., Powles T.J., Dowsett M. The influence of aminoglutethimide and its analogue rogletimide on peripheral aromatisation in breast cancer. British Journal of Cancer 1992, 66(4):692-697.
94. Martin M.B., Franke T.F., Stoica G.E., Chambon P., Katzenellenbogen B.S., Stoica B.A., McLemore M.S., Olivo S.E., Stoica A. A role for Akt in mediating the estrogenic functions of epidermal growth factor and insulin-like growth factor I. Endocrinology 2000, 141(12):4503-4511.
95. Martin L.A., Farmer I., Johnston S.R., Ali S., Marshall C., Dowsett M. Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation. The Journal of Biological Chemistry 2003, 278(33):30458-30468.
96. Masamura S., Santner S.J., Heitjan D.F., Santen R.J. Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. The Journal of Clinical Endocrinology and Metabolism 1995, 80(10):2918-2925.
97. Masi L., Becherini L., Gennari L., Amedei A., Colli E., Falchetti A., Farci M., Silvestri S., Gonnelli S., Brandi M.L. Polymorphism of the aromatase gene in postmenopausal Italian women: distribution and correlation with bone mass and fracture risk. The Journal of Clinical Endocrinology and Metabolism 2001, 86(5):2263-2269.
98. Mauri D., Pavlidis N., Polyzos N.P., Ioannidis J.P. Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. Journal of the National Cancer Institute 2006, 98(18):1285-1291.
99. McClelland R.A., Gee J.M., Francis A.B., Robertson J.F., Blamey R.W., Wakeling A.E., Nicholson R.I. Short-term effects of pure anti-oestrogen ICI 182780 treatment on oestrogen receptor, epidermal growth factor receptor and transforming growth factor-alpha protein expression in human breast cancer. European Journal of Cancer 1996, 32A(3):413-416.
100. McDonnell D.P., Connor C.E., Wijayaratne A., Chang C.Y., Norris J.D. Definition of the molecular and cellular mechanisms underlying the tissue-selective agonist/antagonist activities of selective estrogen receptor modulators. Recent Progress in Hormone Research 2002, 57:295-316.
101. McKenna N.J., Lanz R.B., O'Malley B.W. Nuclear receptor coregulators: cellular and molecular biology. Endocrine Reviews 1999, 20(3):321-344.
102. Mehta R.S., Barlow W.E., Albain K.S., Vandenberg T.A., Dakhil S.R., Tirumali N.R., Lew D.L., Hayes D.F., Gralow J.R., Livingston R.B., et al. Combination anastrozole and fulvestrant in metastatic breast cancer. The New England Journal of Medicine 2012, 367(5):435-444.
103. Metivier R., Penot G., Carmouche R.P., Hubner M.R., Reid G., Denger S., Manu D., Brand H., Kos M., Benes V., et al. Transcriptional complexes engaged by apo-estrogen receptor-alpha isoforms have divergent outcomes. The EMBO Journal 2004, 23(18):3653-3666.
104. Miller W.R., Dixon J.M. Antiaromatase agents: preclinical data and neoadjuvant therapy. Clinical Breast Cancer 2000, 1(Suppl. 1):S9-14.
105. Miller W.R., O'Neill J. The importance of local synthesis of estrogen within the breast. Steroids 1987, 50(4-6):537-548.
106. Miller T.W., Hennessy B.T., Gonzalez-Angulo A.M., Fox E.M., Mills G.B., Chen H., Higham C., Garcia-Echeverria C., Shyr Y., Arteaga C.L. Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. Journal of Clinical Investigation 2010, 120(7):2406-2413.
107. Miller T.W., Rexer B.N., Garrett J.T., Arteaga C.L. Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Research: BCR 2011, 13(6):224.
108. Mouridsen H., Gershanovich M., Sun Y., Perez-Carrion R., Boni C., Monnier A., Apffelstaedt J., Smith R., Sleeboom H.P., Janicke F., et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2001, 19(10):2596-2606.
109. Mouridsen H., Gershanovich M., Sun Y., Perez-Carrion R., Boni C., Monnier A., Apffelstaedt J., Smith R., Sleeboom H.P., Jaenicke F., et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2003, 21(11):2101-2109.
110. Nabholtz J.M., Buzdar A., Pollak M., Harwin W., Burton G., Mangalik A., Steinberg M., Webster A., von Euler M. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2000, 18(22):3758-3767.
111. O'Hara J., Vareslija D., McBryan J., Bane F., Tibbitts P., Byrne C., Conroy R.M., Hao Y., Gaora P.O., Hill A.D., et al. AIB1:ERalpha transcriptional activity is selectively enhanced in aromatase inhibitor-resistant breast cancer cells. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2012, 18(12):3305-3315.
112. Osborne C.K., Coronado-Heinsohn E.B., Hilsenbeck S.G., McCue B.L., Wakeling A.E., McClelland R.A., Manning D.L., Nicholson R.I. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. Journal of the National Cancer Institute 1995, 87(10):746-750.
113. Osborne C.K., Zhao H., Fuqua S.A. Selective estrogen receptor modulators: structure, function, and clinical use. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2000, 18(17):3172-3186.
114. Osborne C.K., Pippen J., Jones S.E., Parker L.M., Ellis M., Come S., Gertler S.Z., May J.T., Burton G., Dimery I., et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2002, 20(16):3386-3395.
115. Paech K., Webb P., Kuiper G.G., Nilsson S., Gustafsson J., Kushner P.J., Scanlan T.S. Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science 1997, 277(5331):1508-1510.
116. Parker M.G. Action of "pure" antiestrogens in inhibiting estrogen receptor action. Breast Cancer Research and Treatment 1993, 26(2):131-137.
117. Pasqualini J.R., Chetrite G., Blacker C., Feinstein M.C., Delalonde L., Talbi M., Maloche C. Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre- and postmenopausal breast cancer patients. The Journal of Clinical Endocrinology and Metabolism 1996, 81(4):1460-1464.
118. Perissi V., Aggarwal A., Glass C.K., Rose D.W., Rosenfeld M.G. A corepressor/coactivator exchange complex required for transcriptional activation by nuclear receptors and other regulated transcription factors. Cell 2004, 116(4):511-526.
119. Pietras R.J., Szego C.M. Specific binding sites for oestrogen at the outer surfaces of isolated endometrial cells. Nature 1977, 265(5589):69-72.
120. Pietras R.J., Arboleda J., Reese D.M., Wongvipat N., Pegram M.D., Ramos L., Gorman C.M., Parker M.G., Sliwkowski M.X., Slamon D.J. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 1995, 10(12):2435-2446.
121. Plourde P.V., Dyroff M., Dukes M. Arimidex: a potent and selective fourth-generation aromatase inhibitor. Breast Cancer Research and Treatment 1994, 30(1):103-111.
122. Plourde P.V., Dyroff M., Dowsett M., Demers L., Yates R., Webster A. ARIMIDEX: a new oral, once-a-day aromatase inhibitor. The Journal of Steroid Biochemistry and Molecular Biology 1995, 53(1-6):175-179.
123. Powles T.J., Hickish T., Kanis J.A., Tidy A., Ashley S. Effect of tamoxifen on bone mineral density measured by dual-energy X-ray absorptiometry in healthy premenopausal and postmenopausal women. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 1996, 14(1):78-84.
124. Rabaglio M., Sun Z., Price K.N., Castiglione-Gertsch M., Hawle H., Thurlimann B., Mouridsen H., Campone M., Forbes J.F., Paridaens R.J., et al. Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO 2009, 20(9):1489-1498.
125. Rakha E.A., El-Sayed M.E., Green A.R., Paish E.C., Powe D.G., Gee J., Nicholson R.I., Lee A.H., Robertson J.F., Ellis I.O. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2007, 25(30):4772-4778.
126. Rakha E.A., Reis-Filho J.S., Ellis I.O. Combinatorial biomarker expression in breast cancer. Breast Cancer Research and Treatment 2010, 120(2):293-308.
127. Reid G., Hubner M.R., Metivier R., Brand H., Denger S., Manu D., Beaudouin J., Ellenberg J., Gannon F. Cyclic, proteasome-mediated turnover of unliganded and liganded ERalpha on responsive promoters is an integral feature of estrogen signaling. Molecular Cell 2003, 11(3):695-707.
128. Revankar C.M., Cimino D.F., Sklar L.A., Arterburn J.B., Prossnitz E.R. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science 2005, 307(5715):1625-1630.
129. Ring A., Dowsett M. Human epidermal growth factor receptor-2 and hormonal therapies: clinical implications. Clinical Breast Cancer 2003, 4(Suppl. 1):S34-41.
130. Robertson J.F. Fulvestrant (Faslodex) - how to make a good drug better. Oncologist 2007, 12(7):774-784.
131. Robertson J.F., Nicholson R.I., Bundred N.J., Anderson E., Rayter Z., Dowsett M., Fox J.N., Gee J.M., Webster A., Wakeling A.E., et al. Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer. Cancer Research 2001, 61(18):6739-6746.
132. Robertson J.F.R.G.E., Cheung K.L., Pinder S., Ellis I.O., Wakeling A. Clinical efficacy of fulvestrant and effects on estrogen receptor levels during first-line endocrine treatment of patients with advanced breast cancer. Breast Cancer Research and Treatment 2004, 88(Suppl. 1):S236-S237.
133. Robertson J.F., Dixon J.M., Sibbering D.M., Jahan A., Ellis I.O., Channon E., Hyman-Taylor P., Nicholson R.I., Gee J.M. A randomized trial to assess the biological activity of short-term (pre-surgical) fulvestrant 500 mg plus anastrozole versus fulvestrant 500 mg alone or anastrozole alone on primary breast cancer. Breast Cancer Research: BCR 2013, 15(2):R18.
134. Sabnis G.J., Goloubeva O., Chumsri S., Nguyen N., Sukumar S., Brodie A.M. Functional activation of the estrogen receptor-alpha and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letrozole. Cancer Research 2011, 71(5):1893-1903.
135. Sanchez C.G., Ma C.X., Crowder R.J., Guintoli T., Phommaly C., Gao F., Lin L., Ellis M.J. Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer. Breast Cancer Research: BCR 2011, 13(2):R21.
136. Santen R.J. Clinical review: effect of endocrine therapies on bone in breast cancer patients. The Journal of Clinical Endocrinology and Metabolism 2011, 96(2):308-319.
137. Santen R., Jeng M.H., Wang J.P., Song R., Masamura S., McPherson R., Santner S., Yue W., Shim W.S. Adaptive hypersensitivity to estradiol: potential mechanism for secondary hormonal responses in breast cancer patients. The Journal of Steroid Biochemistry and Molecular Biology 2001, 79(1-5):115-125.
138. Schiff R., Massarweh S.A., Shou J., Bharwani L., Mohsin S.K., Osborne C.K. Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2004, 10(1 Pt 2):331S-336S.
139. Schrey M.P., Patel K.V. Prostaglandin E2 production and metabolism in human breast cancer cells and breast fibroblasts. Regulation by inflammatory mediators. British Journal of Cancer 1995, 72(6):1412-1419.
140. Shiau A.K., Barstad D., Loria P.M., Cheng L., Kushner P.J., Agard D.A., Greene G.L. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 1998, 95(7):927-937.
141. Shim W.S., Conaway M., Masamura S., Yue W., Wang J.P., Kmar R., Santen R.J. Estradiol hypersensitivity and mitogen-activated protein kinase expression in long-term estrogen deprived human breast cancer cells in vivo. Endocrinology 2000, 141(1):396-405.
142. Simoncini T., Hafezi-Moghadam A., Brazil D.P., Ley K., Chin W.W., Liao J.K. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 2000, 407(6803):538-541.
143. Simpson E.R. Sources of estrogen and their importance. The Journal of Steroid Biochemistry and Molecular Biology 2003, 86(3-5):225-230.
144. Smith I.E., Dowsett M. Aromatase inhibitors in breast cancer. The New England Journal of Medicine 2003, 348(24):2431-2442.
145. Smith C.L., Conneely O.M., O'Malley B.W. Modulation of the ligand-independent activation of the human estrogen receptor by hormone and antihormone. Proceedings of the National Academy of Sciences of the United States of America 1993, 90(13):6120-6124.
146. Smith C.L., Nawaz Z., O'Malley B.W. Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Molecular Endocrinology 1997, 11(6):657-666.
147. Smith I.E., Walsh G., Skene A., Llombart A., Mayordomo J.I., Detre S., Salter J., Clark E., Magill P., Dowsett M. A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2007, 25(25):3816-3822.
148. Sourdaine P., Parker M.G., Telford J., Miller W.R. Analysis of the aromatase cytochrome P450 gene in human breast cancers. Journal of Molecular Endocrinology 1994, 13(3):331-337.
149. Stein R.C., Dowsett M., Hedley A., Gazet J.C., Ford H.T., Coombes R.C. The clinical and endocrine effects of 4-hydroxyandrostenedione alone and in combination with goserelin in premenopausal women with advanced breast cancer. British Journal of Cancer 1990, 62(4):679-683.
150. Stephen R.L., Shaw L.E., Larsen C., Corcoran D., Darbre P.D. Insulin-like growth factor receptor levels are regulated by cell density and by long term estrogen deprivation in MCF7 human breast cancer cells. The Journal of Biological Chemistry 2001, 276(43):40080-40086.
151. Tang Q., Chen Y., Meyer C., Geistlinger T., Lupien M., Wang Q., Liu T., Zhang Y., Brown M., Liu X.S. A comprehensive view of nuclear receptor cancer cistromes. Cancer Research 2011, 71(22):6940-6947.
152. Thomas P., Pang Y., Filardo E.J., Dong J. Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology 2005, 146(2):624-632.
153. Thurlimann B., Keshaviah A., Coates A.S., Mouridsen H., Mauriac L., Forbes J.F., Paridaens R., Castiglione-Gertsch M., Gelber R.D., Rabaglio M., et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. The New England Journal of Medicine 2005, 353(26):2747-2757.
154. Tominaga T., Adachi I., Sasaki Y., Tabei T., Ikeda T., Takatsuka Y., Toi M., Suwa T., Ohashi Y. Double-blind randomised trial comparing the non-steroidal aromatase inhibitors letrozole and fadrozole in postmenopausal women with advanced breast cancer. Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO 2003, 14(1):62-70.
155. Tora L., White J., Brou C., Tasset D., Webster N., Scheer E., Chambon P. The human estrogen receptor has two independent nonacidic transcriptional activation functions. Cell 1989, 59(3):477-487.
156. Vallabhaneni S., Nair B.C., Cortez V., Challa R., Chakravarty D., Tekmal R.R., Vadlamudi R.K. Significance of ER-Src axis in hormonal therapy resistance. Breast Cancer Research and Treatment 2011, 130(2):377-385.
157. Viale G., Regan M.M., Maiorano E., Mastropasqua M.G., Dell'Orto P., Rasmussen B.B., Raffoul J., Neven P., Orosz Z., Braye S., et al. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2007, 25(25):3846-3852.
158. Wakeling A.E., Dukes M., Bowler J. A potent specific pure antiestrogen with clinical potential. Cancer Research 1991, 51(15):3867-3873.
159. Warnmark A., Treuter E., Wright A.P., Gustafsson J.A. Activation functions 1 and 2 of nuclear receptors: molecular strategies for transcriptional activation. Molecular Endocrinology 2003, 17(10):1901-1909.
160. Weigel N.L., Zhang Y. Ligand-independent activation of steroid hormone receptors. Journal of Molecular Medicine (Berlin) 1998, 76(7):469-479.
161. Yardley D.A., Ismail-Khan R.R., Melichar B., Lichinitser M., Munster P.N., Klein P.M., Cruickshank S., Miller K.D., Lee M.J., Trepel J.B. Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2013, 31(17):2128-2135.